Esperion Therapeutics (ESPR) Partnership or Takeout 'Inevitable'; RBC Capital Starts at Outperform
Tweet Send to a Friend
RBC Capital initiated coverage on Esperion Therapeutics (NASDAQ: ESPR) with an Outperform rating and a price target of $150, suggesting ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
